

Michigan State University Biochemistry & Molecular Biology
Graduate Program – “The Exchange, Special Edition” – presents:



Dr. Michael Gilman

CEO, Arrakis Therapeutics

RNA-targeting small drug discovery

Thursday, May 28th 2020

11:00 a.m. EST (Zoom)

Dr. Gilman has a distinguished career in the biotech industry, and his current firm is engaged in the cutting-edge field of RNA-targeting small molecule drugs. Through a new partnership with Roche, Arrakis Therapeutics is poised to significantly expand its efforts to devise novel treatments for human diseases.

Dr. Gilman obtained his Ph.D. in Biochemistry at the University of California, Berkeley, in the area of gene regulation. Following a successful stint as investigator at the Cold Spring Harbor Laboratory, he entered the world of biotechnology, founding a number of successful startups.

Selected Publications:

Gilman MZ and Chamberlin MJ. (1983) Developmental and genetic regulation of *Bacillus subtilis* genes transcribed by sigma 28-RNA polymerase. *Cell* 35: 285-93.

Gilman MZ, Wilson RN and Weinberg RA. (1987) Multiple protein-binding sites in the 5'-flanking region regulate c-fos expression. *Mol Cell Biol* 6: 4305-16.

Sadowski HB, Shuai K, Darnell JE Jr and Gilman MZ. (1993) A common nuclear signal transduction pathway activated by growth factor and cytokine receptors. *Science* 261: 1739-44.

Biotech:

1994-99 Executive VP and CEO, ARIAD Pharmaceuticals

1999-05 Executive VP Research, Biogen

2006-12 Founder and CEO, Stromedix

2012-13 Senior VP, Biogen Idec

2014-16 Founder and CEO, Padlock Therapeutics

2016-19 CEO, Obsidian Therapeutics

2016-present, CEO, Arrakis Therapeutics



Learn more about the recent partnership between Arrakis Therapeutics and Roche in a recent interview with James Sabry, Global Head of Pharma Partnering at Roche and Mike Gilman, CEO of Arrakis Therapeutics:

<https://www.biocentury.com/media/podcast/biocentury-this-week/special-edition-consummating-a-deal-under-lockdown>